For the quarter ending 2026-03-31, URGN made $50,959K in revenue. -$23,585K in net income. Net profit margin of -46.28%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 50,959 | 37,837 | 27,482 | 24,215 |
| Cost of revenue | 4,139 | 3,289 | 3,278 | 3,550 |
| Gross profit | 46,820 | 34,548 | 24,204 | 20,665 |
| Research and development expenses | 15,597 | 14,314 | 14,008 | 18,914 |
| Selling, general and administrative expenses | 51,486 | 39,349 | 37,582 | 43,199 |
| Operating loss | -20,263 | -19,115 | -27,386 | -41,448 |
| Financing on prepaid forward obligation | 4,506 | 4,655 | 4,621 | 4,644 |
| Interest expense on long-term debt | 4,185 | 3,772 | 3,373 | 4,132 |
| Interest and other income, net | 608 | 903 | 979 | 1,299 |
| Loss before income taxes | -28,346 | -26,639 | -34,401 | -48,925 |
| Income tax benefit (expense) | -4,772 | -275 | -1,054 | 1,015 |
| Net loss | -23,574 | -26,364 | -33,347 | -49,940 |
| Unrealized loss on investments | -11 | -4 | 17 | -8 |
| Comprehensive loss | -23,585 | -26,368 | -33,330 | -49,948 |
| Basic EPS | -0.47 | -0.535 | -0.69 | -1.05 |
| Basic Average Shares | 50,182,758 | 49,245,071 | 48,057,386 | 47,739,816 |
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)